
may pm et
summari compani one world largest drug maker larg small molecul
price-to-earnings oper ep
risk assess reflect challeng brand
patent new drug develop regulatori risk
believ rel robust pipelin
jul ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
may stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra keep hold
rais target
slightli peer
ep estim rais
ep estim ep
vs ahead view
sale fx benefit rose driven
keytruda sale year
ago sequenti slightli
slightli ahead
expect solid growth oversea
partial off-set price pressur file
biolog licens applic bla keytruda
combin chemotherapi base
data trial treat
prioriti review bla fda action
date septemb data
trial cut risk death
impress view also sbla
keytruda treat recurr metastat
head neck cancer fda action date
decemb loo cfa
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview merck co lead global drugmak produc wide rang prescript
drug mani therapeut class abroad foreign oper account
total sale respect
early-novemb acquir rival drugmak schering-plough billion cash
largest-sel product includ januvia/janumet sale billion billion
treatment type diabet remicad billion billion
treatment rheumatoid arthriti isentress billio billion treatment
hiv/aid remicad lost patent protect europ late
merck also lead maker vaccin vaccin includ proquad measl mump rubella
chicken pox gardasil human papilloma viru main caus cervic cancer rotateq
purchas schering-plough merck gain total right zetia -- cholesterol therapi
work block cholesterol absorpt intestin -- well vytorin combin pill
contain zocor zetia vytorin sale billion billion
zetia sale billion billion anim health product compris
anti-infect antiparasit drug relat item octob merck sold consum care
product unit includ over-the-counter brand claritin allergi dr scholl foot care product
copperton suntan lotion bayer ag billion
market profil dollar valu global drug market project grow compound-annual-growth-rate compound
annual growth rate period accord forecast made im health
key driver emerg market whose aggreg sale countri advanc compound-annual-growth-rate
period growth develop market spur rise standard
live grow govern spend health care howev im forecast declin trend europ
impact auster price combin drug spend five major european market project
declin compound-annual-growth-rate hand spend forecast
grow compound-annual-growth-rate period
impact major develop expens total billion sale billion
sale billion sale pipelin august
includ five program regulatori review program phase clinic trial program
phase ii clinic trial billion acquisit schering-plough fund cash
billion debt billion merck stock billion octob
complet sale consum care unit includ brand claritin afrin copperton
bayer ag billion
cfo execut vice-president
offic senior vice-president
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc april technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook pharmaceut
sub-industri next month neutral
although believ trump
administr push regulatori
chang forc drug price believ
third parti payer health insur
pharmaci benefit manag pbm along
public pressur media effect
pharmaceut firm announc
rais price drug
year histor drug price increas
account signific portion firm
tweet work new
system competit
drug industri drug price
come follow comment share
price drug firm declin markedli
volatil industri increas
price innov work group
releas draft execut order aim
tackl high drug price draft focus
reduc regul method increas
competit lower drug price strengthen
properti right scale back discount
given hospit serv lower incom
patient import note mani
individu serv work group
former pharmaceut execut like
cfra view put forward
separ believ top-lin pressur
patent expir mani top-sel drug
bottom anticip modest
organ sale increas low-singl digit
howev see modest benefit
foreign exchang follow
soften dollar late
also see expand sale new innov
drug therapi margin improv
accru cost restructur merger
see afford act
continu neg affect industri
margin see benefit includ improv
sale demand signific expans
insur popul accord
depart human servic
insur sinc law enact
howev repeal individu mandat
compon requir
peopl health insur pay fine
includ tax cut job act
pass decemb repeal
mandat effect januari
expect fewer insur patient
despit advers effect patent
expir pressur high drug price
still think long-term prospect
remain one widest-margin
industri prospect enhanc
demograph growth elderli
account industri sale
new drug discoveri number
new molecular entiti approv rebound
approv number
approv sinc
record approv follow robust
approv
approv
 pharmaceut index
increas versu rise
 composit index year date
april
declin composit index
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
keep target price in-lin
forward ep estim ep vs
ahead estim rais ep estim sale fell
partli unfavor impact cyber attack june say
result lost sale ad cost separ keytruda
sale exceed think new indic drive sale
also encourag oncolog collabor astrazeneca
includ co-promot lynparza /jeffrey loo cfa
rais target price in-lin
peer forward ep estim ep vs
ahead estim rais ep estim
sale rose ahead forecast declin driven
robust increas keytruda sale offset
declin sever older key drug januvia
zetia/vytorin look continu robust rise keytruda sale
approv addit oncolog indic /jeffrey loo cfa
keep target in-lin peer
ep estim ep vs in-lin
estim sale rose keytruda sale doubl
forecast sever regulatori action date year
includ fda action date may keytruda combin
chemotherapi treat advanc non-smal cell lung cancer june
keytruda treat bladder cancer anticip fda approv
indic help drive keytruda sale /jeffrey loo cfa
analyst research note compani news
et cfra keep hold opinion share merck co inc
rais target slightli
peer ep estim rais ep
estim ep vs ahead view
sale fx benefit rose driven keytruda sale
year ago sequenti slightli forecast
howev januvia sale growth slightli ahead
expect solid growth oversea partial off-set price pressur
file biolog licens applic bla keytruda combin
chemotherapi base data trial treat non-smal
cell lung cancer fda grant prioriti review bla fda action
date septemb data trial cut risk death
impress view also sbla keytruda treat
recurr metastat head neck cancer fda action date
announc initi result checkmat phase
trial opdivo yervoy combin treat first line advanc
non-smal cell lung cancer trial met primari endpoint one-year
progression-fre surviv compar chemotherapi
overal respons rate versu chemotherapi base earli
analysi data overal surviv encourag critic data
releas yet share sharpli competitor merck
report combin trial -- keynot made keytruda
plu chemotherapi -- cut risk death compar chemotherapi
regardless express includ patient test neg
base trial result think continu maintain
sizeabl market share lung cancer market lower target
price bristol-my squibb ep estim
keep target price slightli
peer ep estim set ep
ep vs ahead estim aid lower tax
rate sale rose slightli forecast keytruda sale
solid view guid sale ep
look continu robust sale keytruda recent approv
lynparza co-partn astrazeneca treat breast cancer
anticip flat sale top sell diabet drug januvia /jeffrey loo
share significantli posit phase
result keytruda combin two chemotherapi drug first
line treatment non-smal cell lung cancer trial met
endpoint overal surviv progression-fre surviv result
submit regul believ bolster chanc approv
europ solidifi lead posit indic
withdrawn eu applic oct trial
meet endpoint fda approv alreadi receiv set /jeffrey
lower target below-p
forward ep estim share
eu file keytruda combin chemotherapi first line
treatment non-smal cell lung cancer fda approv given
set may said modifi phase trial overal
surviv progression-fre surviv believ delay result
see lung cancer among import oncolog indic
see potenti benefit competitor bristol-mey opdivo /jeffrey
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
